SEVERAL INFLAMMATORY CONDITIONS in the lungs are characterized by increased neutrophil recruitment and activation, in particular, airway infections, cystic fibrosis, the acute respiratory distress syndrome, and the chronic obstructive pulmonary disease (7, 14, 31) . Neutrophils are the most abundant cell type among circulating white cells and constitute the first line of host defense against invading microorganisms. Pathogens are removed by phagocytosis and killed in the neutrophil phagosome by reactive oxygen species and proteases. When neutrophils are overactivated, these toxic products can also be released extracellularly and cause substantial bystander tissue damage. Neutrophils have a very short life span in circulation (6 -8 h) and in tissue (1-4 days) (9, 25) . In tissue, they undergo programmed cell death, and apoptotic cells are recognized and removed by macrophages (10, 18) . Cell membrane integrity is maintained during apoptosis, and the massive release of reactive oxygen species and proteases in the tissue is prevented (9) . Moreover, the recognition of apoptotic neutrophils by macrophages leads to the production of anti-inflammatory mediators, such as transforming growth factor-␤ and IL-10 (9). During inflammation, neutrophil apoptosis can be markedly delayed by granulocyte/macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-␥, or toll-like receptor agonists, such as lipopolysaccharide (LPS) (13, 23, 43) . The induction of neutrophil apoptosis using a pharmacological agent might be an interesting approach to accelerate the resolution of inflammation (16, 35, 37) . For instance, cyclin-dependent kinase inhibitors, currently evaluated as anticancer agents in clinical trials, enhanced the resolution of inflammation in mouse models of lung inflammation by promoting neutrophil apoptosis (35) .
Nicotinamide, a component of vitamin B 3 , is known to affect cell survival. Nicotinamide can either promote cell survival or apoptosis, depending on the cell type. Nicotinamide protected neurons against apoptosis during anoxia in vitro and in a rat model of traumatic brain injury in vivo (5, 17) . Nicotinamide also protected human Jurkat T cells against deoxycholateinduced apoptosis in vitro (11) . Conversely, nicotinamide induced apoptosis of rat hepatic stellate cells, human chondrocytes, and several tumor cell lines in vitro (21, 36, 38, 40) . Yet the impact of nicotinamide on neutrophil apoptosis has not been evaluated so far.
Nicotinamide is an essential precursor of NAD. It provides NAD stores during activation of poly(ADP-ribose) polymerase (PARP), a NAD-dependent DNA repair enzyme, and protects against the decreased production of ATP. Nicotinamide is also a byproduct of the enzymatic reaction of NAD and, therefore, a feedback PARP inhibitor. The overactivation of PARP can be detrimental and cause depletion of cellular NAD and ATP supplies and eventually apoptosis. Nicotinamide could effectively prevent apoptosis by providing NAD, through PARP inhibition, or both (2, 17, 24) . Nicotinamide is also a feedback inhibitor of NAD-dependent class III histone deacetylases or sirtuins (SIRT). SIRT1 plays an important role in the regulation of cell fate, DNA repair, aging, and stress response in mammalian cells. It deacetylates not only the lysine residues of histone proteins, but also the lysine residues of some apoptosisinducible nuclear proteins, such as p53 and the forkhead family proteins. The deacetylation of these nuclear proteins by SIRT1 results in the inhibition of apoptosis (20, 27, 39) .
We hypothesized that pulmonary nicotinamide administration could promote the resolution of lung inflammation by inducing neutrophil apoptosis. Therefore, we assessed, in vitro, the impact of nicotinamide on the apoptosis of human blood neutrophils treated or not with G(M)-CSF, and we examined the involvement of caspase-3 in the increased apoptosis. Then we studied the impact of pulmonary nicotinamide delivery on neutrophil apoptosis and inflammation in vivo using a mouse model of endotoxin-induced lung inflammation.
MATERIALS AND METHODS

In Vitro Experiments
Isolation and culture of neutrophils. Human blood neutrophils were isolated from 100-ml buffy-coats (Bloodbank of Liège, Belgium) by density centrifugation using the Histopaque method (specific gravity 1.077; Sigma, Bornem, Belgium). Contaminating erythrocytes were removed by hypotonic lysis, and neutrophils were subsequently washed in phosphate-buffered saline (PBS; Life Technologies, Merelbeke, Belgium). Purity, as determined by cell counting of cytospin preparations stained with Diff-Quick (Dade, Brussels, Belgium), was always Ն95%. Neutrophils were cultured at 10 6 cells/ml in RPMI 1640 medium (Life Technologies, Merelbeke, Belgium), supplemented with 1% glutamine, 10% fetal bovine serum. After 30 min of neutrophil preincubation with or without GM-CSF or G-CSF (25 ng/ml; Peprotech), three nicotinamide doses (2.5, 5, or 10 mM; Fluka, Buchs, Switzerland) were added. Treated neutrophils were incubated in a humidified atmosphere at 37°C for 18 h, before apoptosis determination.
Detection and quantification of apoptotic cells. After neutrophil incubation with the different treatments, cells were washed in PBS, resuspended, and incubated in an annexin-V binding buffer containing annexin-V-phycoerythrin and 7-aminoactinomycin D (Roche Diagnostics, Brussels, Belgium) at room temperature in the dark for 15 min. Analyses were performed by flow cytometry using a FACSAria (BD Biosciences, San Jose, CA).
Assay of caspase-3 activity. Caspase-3 activity was assessed using CaspaTag caspase-3/7 in situ fluorescein assay kits (Chemicon International, Billerica, MA). Caspase fluorochrome inhibitors bind covalently to the active caspase, and the fluorescent signal was measured afterwards by flow cytometry. Briefly, freshly isolated human blood neutrophils were preincubated for 30 min with or without GM-CSF. After the preincubation period, nicotinamide (5 and 10 mM) was added or not, and neutrophils were incubated for 18 h.
Neutrophil chemotaxis. The experiment of neutrophil chemotaxis was performed in 48-well microchemotaxis Boyden chambers, as described elsewhere (8) . Briefly, isolated human neutrophils were resuspended in Hanks' balanced salt solution (HBSS; Gibco, Merelbeke, Belgium) with Ca 2ϩ and Mg 2ϩ and 0.2% of bovine serum albumin (Sigma, Bornem, Belgium). Neutrophils were preincubated for 10 min with nicotinamide (2.5, 5, or 10 mM). Negative and positive controls were, respectively, HBSS and casein-activated serum. Casein-activated serum was prepared by mixing casein (75 ng/ml), HBSS, and serum (1:1:1). HBSS or casein-activated serum was placed in the lower chamber compartments, while the cell suspension (10 6 cells/ml) was placed in the upper chamber compartments. A 0.8-m polycarbonate polyvinylpyrrolidone-free filter (Nucleopore; Whatman, Piscataway, NJ) was placed between the upper and lower compartments. Chambers were incubated in 5% carbon dioxide at 37°C for 1 h. The filters were removed, and nonmigrated cells were scraped from the upper surface of the filters. Filters were stained with Diff-Quick, and migrated cells were counted in 10 fields/ per well at magnification of ϫ1,000.
In Vivo Airway Inflammation Model
Mice. Specific-pathogen-free male C57BL/6N mice (Elevage Janvier, Le Genest-St.-Isle, France), aged between 8 and 10 wk, were used in this study. Mice were maintained in a room with controlled temperature and humidity and with a 12:12-h light-dark cycle. Mice were fed ad libitum. All experimental protocols in mice were approved by the Institutional Animal Care and Use Committee of the Université catholique de Louvain (Brussels, Belgium).
Treatment protocol. The experimental protocol was performed as described in Fig. 1 . Airway inflammation in mice was induced by intratracheal administration of LPS. Before intratracheal instillation of any solution, mice were anesthetized using ketamine-xylazine (90:10 mg/kg) intraperitoneal injection. Five micrograms of LPS (Escherichia coli O111:B4, Sigma) in 25 l of PBS were administered to each mouse using a 100-l precision microsyringe (Hamilton, Bonaduz, Switzerland), followed by insufflation of a 200-l air bolus to push the solution into the deep lung (26) . PBS was administered to negative controls. Nicotinamide (10 mg/kg) was administered intratracheally in 25 l of PBS 2 h before or 2 h after LPS administration. At selected time points (see Fig. 1 ), mice were killed by a lethal intraperitoneal injection of pentobarbital. A bronchoalveolar lavage (BAL) was performed by cannulating the trachea and instilling twice 1 ml HBSS containing a cocktail of protease inhibitors (Roche Diagnostics, Mannheim, Germany). Both aliquots were pooled, and the pool was centrifuged at 280 g, 4°C, for 10 min. The cell pellet was resuspended in 200 l of HBSS, and the total number of cells was counted using Türch staining. Differential cell counts were performed on cytospin preparations using DiffQuick staining. The supernatant was aliquoted and used for biochemical measurements or stored at Ϫ20°C for later cytokine analysis. ajplung.physiology.org LDH activity and proteins assessment. Total protein content and lactate dehydrogenase (LDH) activity were measured spectrophotometrically in BAL performed 24 h after LPS instillation using commercially available kits (Synchron LX Systems, Fullerton, CA). Proteins in BAL were measured by reaction with pyrogallol red and molybdate to form a purple complex that has a maximum absorbance at 600 nm. LDH activity was assessed by monitoring the reduction of NAD ϩ to NADH at 340 nm in the presence of lactate. Chemokine assays. Chemokines were assessed 5 h post-LPS, and levels of keratinocyte chemokine (KC) and macrophage inflammatory protein-2 (MIP-2) were determined in 50 l of BAL samples using a kit (Bio-Plex Multiplex; Bio-Rad, Nazareth, Belgium) and Luminex technology (Bio-Plex; Bio-Rad), according to the recommendations of the manufacturer.
Neutrophil apoptosis detection. Freshly BAL cells isolated 36 h after intratracheal administration of LPS were washed, stained, and analyzed by flow cytometry. Flow cytometry analyses were performed with a FACSAria (BD Biosciences). Neutrophils were stained with anti-mouse Gr-1-allophycocyanin (BD Biosciences). Apoptosis was assessed by staining with annexin-V-FITC and propidium iodide (PI) using annexin-V-FITC Apoptosis Detection kit (BD Biosciences). Samples were gated on the population of neutrophils using a forward scatter and highly GR-1-allophycocyanin positive cells (GR1 hi cells). Gated cells were defined as apoptotic (Annexinϩ/PIϪ), secondary necrotic (Annexinϩ/PIϩ), or neither apoptotic nor necrotic (AnnexinϪ/PIϪ). Results were expressed as percentage of the total population of granulocytes.
Statistical Analysis
Results are expressed as mean Ϯ SE. Data were analyzed using the JMP version 4.0. (Fig. 7) . Statistical significance was set at P Ͻ 0.05.
RESULTS
Nicotinamide Decreased the Survival of G(M)-CSF-treated Neutrophils In Vitro
To investigate whether nicotinamide could regulate neutrophil apoptosis, human blood neutrophils were cultured for 18 h in the presence or absence of nicotinamide. Incubation with nicotinamide alone did not significantly affect neutrophil survival ( Fig. 2A) . When neutrophils were pretreated with GM-CSF or G-CSF, the percentage of neutrophils surviving after 18 h increased twice. Nicotinamide decreased neutrophil survival in a dose-dependent manner after pretreatment with GM-CSF or G-CSF, with a complete disappearance of the protection conferred by the apoptosis inhibitors at the highest nicotinamide concentration (Fig. 2A) . Figure 2B shows typical flow cytometric profiles of neutrophil apoptosis after different treatments.
Nicotinamide Increased Caspase-3 Activation in GM-CSFtreated Neutrophils In Vitro
The caspase signaling cascade can be triggered via two major pathways: the receptor-mediated pathway, and the mitochondria-mediated pathway. In both cases, the downstream effector caspase-3 is activated, which leads to the death cascade (6) . To further understand the mechanism involved in the proapoptotic effect of nicotinamide in GM-CSF-treated human blood neutrophils, we evaluated the degree of activation of the effector caspase-3 by using caspase fluorochrome inhibitors. Incubation of neutrophils with nicotinamide alone did not significantly increase caspase-3 activation (Fig. 3A) . Conversely, the incubation of neutrophils with the apoptosis inhibitor, GM-CSF, significantly reduced caspase-3 activation. Neutrophils simultaneously treated with GM-CSF and nicotinamide showed increased activation of caspase-3 in a dose-dependent manner. The highest dose of nicotinamide completely counteracted the inhibition of caspase-3 activation conferred by GM-CSF (Fig.  3A) . Figure 3B shows typical flow cytometric profiles of caspase-3 activation in neutrophils treated with GM-CSF alone or together with nicotinamide.
Nicotinamide Decreased Neutrophil Chemotaxis In Vitro
The recruitment of neutrophils into the lung is a crucial step in lung inflammatory response. Therefore, we evaluated the effect of nicotinamide on neutrophil chemotaxis using Boyden chambers. Casein-activated serum induced a strong increase of neutrophil chemotaxis compared with the negative control (HBSS). Nicotinamide slightly decreased neutrophil chemotaxis induced by casein-activated serum in a dose-dependent manner (Fig. 4) .
Pulmonary Nicotinamide Delivery Reduced Airway Inflammation In Vivo
Because nicotinamide markedly increased the apoptosis of G(M)-CSF-treated human blood neutrophils and slightly decreased their recruitment in vitro, we evaluated its impact on Fig. 4 . Effect of NAM on neutrophil chemotaxis in vitro. NAM decreased neutrophil chemotaxis in a dose-dependent manner. Neutrophils were pretreated with increasing doses of NAM for 10 min and placed in Boyen microchambers, with or without casein-activated serum for 1 h. Migrating cells were counted in 10 high-power fields. Results are expressed as percentage of maximum response. Results are presented as means Ϯ SE (n ϭ 9 -12) from 3 independent experiments. Groups are significantly different from positive control, neutrophils incubated with casein-activated serum: **P Ͻ 0.01 and ***P Ͻ 0.001. Fig. 5 . Effect of pulmonary NAM delivery on macrophage inflammatory protein-2 (MIP-2; A) and keratinocyte chemokine (KC; B) levels in BAL. NAM did not reduce the production of proinflammatory chemokines. Chemokines were measured by multiplex analysis in BAL obtained 5 h after IT instillation of PBS or LPS (see Fig. 1 ). All values are expressed as pg/ml. Data are presented as means Ϯ SE (n ϭ 6). Groups are significantly different from the LPS group, ***P Ͻ 0.001. the resolution of pulmonary inflammation in a mouse model of endotoxin-induced lung inflammation in vivo (Fig. 1) . The intratracheal administration of LPS induces an acute lung inflammation that is characterized by a massive production of proinflammatory chemokines in the early hours (Fig. 5) , resulting in neutrophil recruitment into the airways (Fig. 6B) . We observed the influx of cells as early as 5 h post-LPS. It peaked at 24 h and remained high up to 36 h post-LPS (Fig. 6A) . The activation and recruitment of neutrophils generate the production of proteases and free radicals that can be responsible for lung injury (Fig. 7) (26) .
Pulmonary nicotinamide administration post-LPS reduced the total number of BAL cells, compared with LPS-treated mice (Fig. 6A) . The cell differential counting indicated that this reduction originated from a decrease in neutrophil counts (Fig.  6B) . In contrast, nicotinamide delivered 2 h before (instead of 2 h after) LPS administration did not significantly decrease total cell counts in BAL, nor neutrophil counts, compared with the LPS-treated-only group (Fig. 6) . Intratracheal LPS instillation induced a transient increase in macrophage counts in BAL at 5 h, which was not altered by nicotinamide administration post-LPS (Fig. 6C) .
Pulmonary nicotinamide delivery attenuated the endotoxininduced lung injury (Fig. 7) . Mice treated with nicotinamide 2 h after LPS showed decreased LDH activity and total protein content, compared with LPS-treated-only mice. However, consistently with cellular inflammation markers, nicotinamide delivered 2 h before LPS did not alleviate lung injury (Fig. 7) .
Nicotinamide administration did not reduce the production of proinflammatory chemokines in LPS-treated mice. The intratracheal instillation of nicotinamide neither 2 h before nor 2 h after LPS affected the levels of KC and MIP-2 in BAL, compared with the LPS-treated-only group (Fig. 5) . (3, 5, 16, 24 , and 36 h) after IT instillation of PBS or LPS (see Fig. 1 ), BALs were performed, and total and differential cell numbers were counted. BAL total cell number (A), neutrophil number (B), and macrophage number (C) are expressed as number of cells ϫ 10 3 /ml. Results are presented as means Ϯ SE (n ϭ 5-10). Only significant differences with LPS group for each time point are indicated: *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001. Fig. 7 . Effect of pulmonary NAM delivery on LDH activity (A) and total protein content (B). NAM administered 2 h post-LPS reduced LDH activity and protein content in BAL. The injury markers were assessed in BAL performed 24 h after IT instillation of PBS or LPS (see Fig. 1 ). Results are presented as means Ϯ SE (n ϭ 9 -10). *Significant difference from the LPS group (Student's t-test, P Ͻ 0.05). 
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Pulmonary Nicotinamide Delivery Increased Neutrophil Apoptosis In Vivo
Finally, we assessed the impact of nicotinamide on airway neutrophil apoptosis in vivo, using BAL cells isolated 36 h post-LPS. Neutrophils from mice treated with LPS and then nicotinamide showed a statistically significant reduction in neutrophil survival (AnnexinϪ/PIϪ) compared with neutrophils from LPS-treated-only mice (Fig. 8A) . This reduction in neutrophil survival was associated with an increase in apoptotic neutrophils (Annexinϩ/PIϪ, Fig. 8B ). Figure 8C shows typical flow cytometric profiles of BAL neutrophils (high positive GR-1, P1) and typical flow cytometric profiles of neutrophil apoptosis from LPS and LPS/nicotinamide mice. Figure 8D provides representative photomicrographs of BAL cellular population at 36 h.
DISCUSSION
This study identifies nicotinamide as a compound capable of accelerating apoptosis of G(M)-CSF-treated neutrophils, what contributes to the resolution of lung inflammation in vivo. Nicotinamide promoted apoptosis of human blood neutrophils in a dose-dependent manner in the presence of powerful apoptosis inhibitors in vitro (Fig. 2) . Its proapoptotic effect was associated with enhanced caspase-3 activity (Fig. 3) . In addition, nicotinamide slightly decreased neutrophil chemotaxis in a dose-dependent manner (Fig. 4) . In a mouse model of endotoxin-induced lung inflammation, pulmonary nicotinamide delivery reduced cellular and biochemical markers of inflammation (Figs. 6 and 7) and increased the percentage of apoptotic neutrophils in BALs (Fig. 8) .
Nicotinamide pro-apoptotic effect was a caspase-dependent mechanism. Caspases have a fundamental role in initiating and executing neutrophil apoptosis (25) . Nicotinamide increased the activation of the effector caspases-3 in the presence of the prosurvival mediator GM-CSF (Fig. 3) , in line with previous work (38, 40 ). Yet the mechanism by which nicotinamide activated the caspase pathway remains to be established in our models. Clues on a potential mechanism might be found in the literature. Jung-Hynes and Ahmad (20) found that specific inhibition of SIRT1 by short hairpin RNA activated the proapoptotic FoxO1 transcription factor in human prostate cancer cells. Takayama et al. (38) showed that SIRT1-specific inhibition by small interfering RNA increased the amount of Bax and reduced the amount of Bcl-2 in the mitochondrial fraction, increased the amounts of cleaved caspase-3 and caspase-9, and increased the percentage of terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling-positive cells in human chrondrocytes. Although nicotinamide is a feedback inhibitor of both PARPs and SIRT, the expression of these enzymes in neutrophils is distinct. PARP is downregulated during neutrophilic differentiation and is absent in mature neutrophils (3) . In contrast, SIRT1 is highly expressed in ajplung.physiology.org mature neutrophils (44) , suggesting that nicotinamide proapoptotic effect in neutrophils is likely a SIRT1-mediated process.
Neutrophils undergoing apoptosis in the inflamed lung in vivo are rapidly taken up by alveolar macrophages (10) . Therefore, an increased percentage of apoptotic neutrophils is not easy to detect in the local neutrophil population. Nonetheless, we observed a proapoptotic effect of pulmonary nicotinamide delivery on neutrophils collected from mouse lungs post-LPS in vivo (Fig. 8) . Our hypothesis is that the increased resolution of inflammation induced by nicotinamide might be related to the acceleration of neutrophil apoptosis and the subsequent clearance of apoptotic neutrophils by alveolar macrophages. In the lung, LPS promotes the production of both GM-CSF and G-CSF, two strong prosurvival cytokines (4, 34) . It is noteworthy that nicotinamide induced neutrophil apoptosis in the presence of these apoptosis inhibitors both in vitro and in vivo (Figs. 2 and 8) .
The recruitment of neutrophils into the lung is a crucial step in lung inflammatory response and a significant number of chemoattractants have been described such as N-formylated peptides derived from bacterial products, the complement component C5a, leukotriene B4, and a large group of chemokines (32) . Therefore, we also assessed if nicotinamide could modulate neutrophil recruitment. Using an in vitro model of neutrophil chemotaxis, we observed that nicotinamide decreased neutrophil migration induced by casein-activated serum. These results are in agreement with a previous study, which showed the inhibition of neutrophil mono(ADP-ribosyl) transferase by nicotinamide with subsequent inhibition of the polymerization of monomeric actin and neutrophil chemotaxis (1). Nicotinamide modulated neutrophil chemotaxis to a lesser extent than it modulated neutrophil apoptosis. Nicotinamide 10 mM completely counteracted the prosurvival effect of G(M)-CSF, whereas the same concentration of nicotinamide only reduced 40% of neutrophil chemotaxis.
Nicotinamide has previously been shown to reduce LPSinduced inflammation in varying models (15, 22, 41, 42) . Kao et al. (22) showed that systemic nicotinamide exerted protective effects on lung dysfunction and acute lung injury caused by systemic endotoxin in rats in vivo and in the isolated rat lungs ex vivo. Van Gool et al. demonstrated that systemic nicotinamide totally protected mice from a lethal injected dose of LPS (42) . These previous studies indicated an association between reduced inflammation and decreased levels of proinflammatory cytokines and chemokines. In contrast to these studies, no impact of nicotinamide was found on the production of chemokines in our model (Fig. 5) . In these previous studies, a large dose (Ͼ200 mg/kg) of nicotinamide was delivered systemically, whereas we delivered a small dose (10 mg/kg) of nicotinamide locally in the lungs, which might explain these discrepancies (22, 42) . Given that chemokines, such as IL-8 in humans or MIP-2 and KC in mice, are important stimuli for neutrophil recruitment (30, 31) , these results reinforce our hypothesis that the decreased neutrophil counts in the lungs and the reduced inflammation could be partly associated with the proapoptotic effect of nicotinamide.
The local administration of nicotinamide to the lungs had significant impact on endotoxin-induced lung inflammation (Figs. 6 and 7) , while one intraperitoneal injection of nicotinamide at a dose of 500 mg/kg failed to reduce pulmonary inflammation in our model (data not shown). We did not assess oral nicotinamide administration because the bacterial nicotinamidase in the intestinal lumen metabolizes nicotinamide to nicotinic acid, a less anti-inflammatory compound (19, 29) . Pulmonary drug delivery presents significant advantages for treating the lungs: drug targeting to the diseased tissue, the use of small doses, and thereby decreased systemic side effects (12) .
Pulmonary administration of nicotinamide 2 h before LPS did not reduce inflammation, in contrast to nicotinamide delivered 2 h after LPS (Figs. 6 and 7) . The recruitment of neutrophils into the lung is a sequential process that starts by the sequestration of neutrophils in the pulmonary vasculature, followed by transendothelial migration into the lung interstitium and transepithelial migration into the alveolar space. Reutershan and colleagues (33) showed that aerosolized LPS induced a rapid sequestration of neutrophils in the pulmonary vasculature, and, 1 h after LPS administration, neutrophils were found in the lung interstitium. Transepithelial migration of neutrophils from the interstitium into the alveolar space was delayed, and the number of neutrophils in BAL significantly increased only 4 h after inhalation of LPS (33) . Given the physicochemical properties of nicotinamide (negative log P and small molecular weight), it is expected to be absorbed within a few tens of minutes from the air spaces into the systemic circulation (28) . Therefore, nicotinamide delivered 2 h after LPS will encounter neutrophils retained in the lung vasculature and interstitium (neutrophils that will later migrate into the alveolar space), while nicotinamide delivered 2 h before LPS will not.
In conclusion, the present study describes nicotinamide as an apoptosis inducer in neutrophils cultured with G(M)-CSF and in vivo in an endotoxin-induced lung inflammation model. Although further studies are needed to clarify the mechanism behind nicotinamide proapoptotic effect in neutrophils, our study underlines a new anti-inflammatory effect of nicotinamide in neutrophilic inflammation. We also suggest confirming nicotinamide proapoptotic effect in chronic models of neutrophilic inflammation, such as murin models of chronic obstructive pulmonary disease and cystic fibrosis.
